Outcome Of The Board Meeting Held On August 13, 2026

Q1FY27 results (unaudited): Standalone: Revenue 3.5bn +18.7% y-y (2.9bn) EBITDA 0.62bn +42.0% y-y (0.44bn) EBITDA margin 17.7% (14.8%) +290 bps y-y PAT 0.42bn +60.7% y-y (0.26bn) Consolidated: Revenue 3.7bn +19.7% y-y (3.1bn) EBITDA 0.62bn +40.0% y-y (0.44bn) EBITDA margin 16.8% (14.3%) +250 bps y-y PAT 0.42bn +60.0% y-y (0.26bn) Commentary: Sales momentum remained strong with double-digit value and volume growth; standalone gross margin healthy at 45.3% despite supply chain disruptions; EBITDA and PAT margins expanded significantly aided by treasury income gains; subsidiary Apple Chemie grew 40.1% but faced margin headwinds from rising raw material costs and inventory buildup.